{"nctId":"NCT03269344","briefTitle":"Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer","startDateStruct":{"date":"2017-06-05","type":"ACTUAL"},"conditions":["Oropharynx Cancer"],"count":65,"armGroups":[{"label":"Control Arm","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Oral Capsule"]},{"label":"Experimental Arm","type":"EXPERIMENTAL","interventionNames":["Drug: Gabapentin"]}],"interventions":[{"name":"Gabapentin","otherNames":[]},{"name":"Placebo Oral Capsule","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients being treated with combination chemotherapy and radiation therapy daily for locally advanced (stage III-IV) squamous cell carcinoma of the oropharynx.\n* Age ≥ 18.\n* ECOG performance status ≤ 1.\n* Patients must provide study specific informed consent prior to study entry and be able to fill out toxicity and quality of life related questionnaires.\n\nExclusion Criteria:\n\n* Patients may not be receiving gabapentin, any other investigational agents, or other anticonvulsants.\n* Patients with metastatic disease are excluded from this clinical trial.\n* Patient with allergies or hypersensitivity to gabapentin.\n* Patients receiving surgery as part of their definitive management.\n* Patients who have received prior chemotherapy or radiation therapy.\n* Patients unable to complete the required forms; however, verbal completion is adequate if recorded on the form daily.\n* Uncontrolled serious illness including, but not limited to, ongoing or serious active infection requiring IV antibiotics for over 30 days, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia other than chronic, stable atrial fibrillation, or psychiatric illness/social situations that would limit compliance with study requirements.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Quality of Life From Mucositis-related Pain Measured by the Patient-Reported Oral Mucositis Symptoms (PROMS) Scale From Baseline to Follow-up","description":"Scale tile: Patient Reported Oral Mucositis Symptoms scale, range 0-1000, higher scores indicate worse outcomes","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1","spread":"16.8"},{"groupId":"OG001","value":"29.1","spread":"22.5"}]}]}]},{"type":"SECONDARY","title":"Change in Total FACT-HN Scores From Baseline to Follow-up","description":"Scale: Functional Assessment of Cancer Therapy-Trial Outcome (FACT-HN), range 0-148, higher scores indicate better outcomes","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.0","spread":null},{"groupId":"OG001","value":"-20.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Opioid Use, Measured in Morphine Equivalents Per Day.","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null},{"groupId":"OG001","value":"22.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in PRO-CTCAE Scores From Baseline to Follow-up","description":"Scale: Patient-reported outcomes of Common Terminology Criteria for Adverse Events (PRO-CTCAE), 5-point Likert scale, higher scores indicate worse outcomes. Range of scores 0-40 (min-max).","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"6.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Weight Lost","description":"Percent weight lost from baseline to week 7 of treatment (end of treatment)","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.7","spread":null},{"groupId":"OG001","value":"-11.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Feeding Tube Placement","description":"Measure of number of patients who required feeding tube placement at any time during the study period","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":29},"commonTop":[]}}}